MARY THOMASSEN

Summary

Affiliation: East Carolina University
Country: USA

Publications

  1. pmc Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation
    Barbara P Barna
    Division or Pulmonary, Critical Care and Sleep Medicine, East Carolina University, Brody Medical Sciences Building, 600 Moye Blvd Rm 3E 149, Greenville, NC 27834, USA
    Int J Mol Sci 14:23858-71. 2013
  2. pmc Alveolar macrophages of GM-CSF knockout mice exhibit mixed M1 and M2 phenotypes
    Heidi Dalrymple
    Program in Lung Cell Biology and Translational Research, Division of Pulmonary, Critical Care Medicine and Sleep Medicine, East Carolina University, Brody School of Medicine, 3E 149 Brody Medical Sciences Building, Greenville, NC 27834, USA
    BMC Immunol 14:41. 2013
  3. pmc The role of PPARγ in carbon nanotube-elicited granulomatous lung inflammation
    Isham Huizar
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, The Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
    Respir Res 14:7. 2013
  4. pmc Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis
    Anagha Malur
    Program in Lung Cell Biology and Translational Research, Division of Pulmonary, Critical Care and Sleep Medicine, East Carolina University, Greenville, NC, USA
    Respir Res 13:46. 2012
  5. ncbi request reprint ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
    Mary Jane Thomassen
    Program in Lung Cell Biology and Translational Research, Division of Pulmonary and Critical Care Medicine, East Carolina University, Greenville, NC, USA
    J Lipid Res 48:2762-8. 2007
  6. pmc An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
    M S Kavuru
    Division of Pulmonary, East Carolina University, Brody School of Medicine, 3E 149 Brody Medical Sciences Building, Greenville, NC 27834, USA
    Eur Respir J 38:1361-7. 2011
  7. doi request reprint PPARgamma regulates the expression of cholesterol metabolism genes in alveolar macrophages
    Anna D Baker
    Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, East Carolina University, Greenville, NC 27834, USA
    Biochem Biophys Res Commun 393:682-7. 2010
  8. pmc Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism
    Anna D Baker
    Department of Internal Medicine, East Carolina University, Greenville, NC, USA
    J Lipid Res 51:1325-31. 2010
  9. doi request reprint Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response
    Anagha Malur
    Department of Internal Medicine, Division of Pulmonary and Critical Care and Sleep Medicine, East Carolina University, Greenville, NC 27834, USA
    J Immunol 182:5816-22. 2009
  10. doi request reprint A novel 1,25-dihydroxyvitamin D-activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP)
    Barbara P Barna
    Division of Pulmonary and Critical Care Medicine, The Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
    Autoimmunity 42:56-62. 2009

Research Grants

  1. GM-CSF THERAPY FOR ALVEOLAR PROTEINOSIS
    Mary Jane Thomassen; Fiscal Year: 2003
  2. Cytokine Dysregulation in GM-CSF Autoimmunity
    Mary Jane Thomassen; Fiscal Year: 2007

Collaborators

  • Isham Huizar
  • Christopher Wingard
  • Tracey L Bonfield
  • Shobha Ghosh
  • Sergio Arce
  • Bruce C Trapnell
  • Steve Meaney
  • Anagha Malur
  • Barbara P Barna
  • Mani S Kavuru
  • Achut G Malur
  • Anna D Baker
  • Baisakhi Raychaudhuri
  • Heidi Dalrymple
  • Susamma Abraham
  • Daniel A Culver
  • Saiprakash B Venkateshiah
  • Irene Marshall
  • M S Kavuru
  • Reema Karnekar
  • Almedia J Mccoy
  • Michiko Kobayashi
  • Carol F Farver
  • Larry Dobbs
  • Mark Jacob
  • Matthew McPeek
  • I Marshall
  • R Karnekar
  • H Dalrymple
  • M Meziane
  • A Malur
  • Greg Wells
  • B P Barna
  • Ravinder J Singh
  • Donald Brescia
  • Tom D Yan
  • Moulay Meziane
  • Carmen Czich
  • Judith A Drazba
  • Nejimole John
  • Samuel J Goldman
  • Todd Rambasek
  • Aaron R Winkler
  • Amitabha Deb
  • Joseph A DiDonato

Detail Information

Publications28

  1. pmc Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation
    Barbara P Barna
    Division or Pulmonary, Critical Care and Sleep Medicine, East Carolina University, Brody Medical Sciences Building, 600 Moye Blvd Rm 3E 149, Greenville, NC 27834, USA
    Int J Mol Sci 14:23858-71. 2013
    ..Findings suggest that Twist1 represents a PPARγ-sensitive alveolar macrophage M1 biomarker which is induced by inflammatory granulomatous disease in the MWCNT model and in human sarcoidosis. ..
  2. pmc Alveolar macrophages of GM-CSF knockout mice exhibit mixed M1 and M2 phenotypes
    Heidi Dalrymple
    Program in Lung Cell Biology and Translational Research, Division of Pulmonary, Critical Care Medicine and Sleep Medicine, East Carolina University, Brody School of Medicine, 3E 149 Brody Medical Sciences Building, Greenville, NC 27834, USA
    BMC Immunol 14:41. 2013
    ..Both human PAP and mouse GM-CSF knockout AMs are deficient in the transcription factor, peroxisome proliferator activated receptor gamma (PPARγ)...
  3. pmc The role of PPARγ in carbon nanotube-elicited granulomatous lung inflammation
    Isham Huizar
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, The Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
    Respir Res 14:7. 2013
    ..Based on such observations we hypothesized that PPARγ expression would be repressed in alveolar macrophages from animals bearing granulomas induced by MWCNT instillation...
  4. pmc Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis
    Anagha Malur
    Program in Lung Cell Biology and Translational Research, Division of Pulmonary, Critical Care and Sleep Medicine, East Carolina University, Greenville, NC, USA
    Respir Res 13:46. 2012
    ..Rituximab treatment decreased anti-GM-CSF antibody levels in bronchoalveolar lavage (BAL) fluid, and 7/9 patients completing the trial demonstrated clinical improvement as measured by arterial blood oxygenation...
  5. ncbi request reprint ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
    Mary Jane Thomassen
    Program in Lung Cell Biology and Translational Research, Division of Pulmonary and Critical Care Medicine, East Carolina University, Greenville, NC, USA
    J Lipid Res 48:2762-8. 2007
    ..These findings document the existence of ABCG1 deficiency in human lung disease and highlight a critical role for ABCG1 in surfactant homeostasis...
  6. pmc An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
    M S Kavuru
    Division of Pulmonary, East Carolina University, Brody School of Medicine, 3E 149 Brody Medical Sciences Building, Greenville, NC 27834, USA
    Eur Respir J 38:1361-7. 2011
    ....
  7. doi request reprint PPARgamma regulates the expression of cholesterol metabolism genes in alveolar macrophages
    Anna D Baker
    Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, East Carolina University, Greenville, NC 27834, USA
    Biochem Biophys Res Commun 393:682-7. 2010
    ..These results suggest that PPARgamma regulates cholesterol metabolism in alveolar macrophages...
  8. pmc Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism
    Anna D Baker
    Department of Internal Medicine, East Carolina University, Greenville, NC, USA
    J Lipid Res 51:1325-31. 2010
    ..These results suggest that PPARgamma mediates a critical role in surfactant homeostasis through the regulation of ABCG1...
  9. doi request reprint Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response
    Anagha Malur
    Department of Internal Medicine, Division of Pulmonary and Critical Care and Sleep Medicine, East Carolina University, Greenville, NC 27834, USA
    J Immunol 182:5816-22. 2009
    ..These results suggest that lack of PPARgamma in alveolar macrophages disrupts lung homeostasis and results in a Th1-like inflammatory response...
  10. doi request reprint A novel 1,25-dihydroxyvitamin D-activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP)
    Barbara P Barna
    Division of Pulmonary and Critical Care Medicine, The Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
    Autoimmunity 42:56-62. 2009
    ..Results suggest that mechanisms of activin A deficiency in PAP alveolar macrophages may involve dysregulation of a novel species-specific vitamin D-activin A pathway...
  11. doi request reprint Restoration of PPARγ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice
    Anagha Malur
    East Carolina Univ, Greenville, NC 27834, USA
    Am J Physiol Lung Cell Mol Physiol 300:L73-80. 2011
    ..In vivo instillation of lenti-PPARγ results in: 1) upregulating ABCG1 and PPARγ expression of GM-CSF KO alveolar macrophages, 2) reducing intracellular lipid accumulation, and 3) increasing cholesterol efflux activity...
  12. ncbi request reprint Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis
    Tracey L Bonfield
    Department of Pulmonary and Critical Care Medicine, 9500 Euclid Avenue, Cleveland Clinic Foundation, Desk A90, Cleveland, OH 44195 5038
    Am J Respir Cell Mol Biol 29:677-82. 2003
    ..Moreover, GM-CSF treatment of patients with PAP fully restores PPAR-gamma to healthy control levels. Based upon these novel findings, we hypothesize that GM-CSF regulates lung homeostasis via PPAR-gamma-dependent pathways...
  13. ncbi request reprint Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor
    Tracey L Bonfield
    Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195 5038, USA
    J Leukoc Biol 79:133-9. 2006
    ..These data suggest that in the absence of GM-CSF, excess M-CSF in PAP may redirect alveolar macrophage activation, thus potentially contributing to elevated MMP expression in the lung...
  14. pmc Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor
    Tracey L Bonfield
    Department of Pediatrics, Case Western Reserve University, Cleveland, OH 44109, USA
    J Immunol 181:235-42. 2008
    ..Taken together, these data suggest that M-CSF is an important mediator of alveolar macrophage homeostasis, and that transcriptional control of M-CSF production is regulated by NF-kappaB and PPARgamma...
  15. ncbi request reprint Depressed peroxisome proliferator-activated receptor gamma (PPargamma) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon gamma (IFN-gamma)
    Barbara P Barna
    Department of Pulmonary, Allergy, and Critical Care Medicine, Lerner Research Institute, The Cleveland Clinic Foundation, OH 44195, USA
    Sarcoidosis Vasc Diffuse Lung Dis 23:93-100. 2006
    ....
  16. ncbi request reprint An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis
    Saiprakash B Venkateshiah
    Department of Pulmonary, Allergy and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, Mail Code A 90, Cleveland, OH 44109, USA
    Chest 130:227-37. 2006
    ..These data indicate that subcutaneous GM-CSF therapy is a promising alternative to WLL for symptomatic patients with PAP...
  17. ncbi request reprint Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis
    Tracey L Bonfield
    Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195 5038, USA
    Clin Immunol 105:342-50. 2002
    ..Together, these data support the hypothesis that PAP is an anti-GM-CSF autoimmune disease due to the development of antibodies, which results in the deactivation or neutralization of GM-CSF...
  18. ncbi request reprint PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor
    Tracey L Bonfield
    Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195 5038, USA
    Am J Physiol Lung Cell Mol Physiol 285:L1132-6. 2003
    ..1 and M-CSFR expression in alveolar macrophages compared with healthy control and PAP patients before GM-CSF therapy. These observations suggest that PU.1 is critical in the terminal differentiation of human alveolar macrophages...
  19. ncbi request reprint Surfactant blocks lipopolysaccharide signaling by inhibiting both mitogen-activated protein and IkappaB kinases in human alveolar macrophages
    Baisakhi Raychaudhuri
    Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Respir Cell Mol Biol 30:228-32. 2004
    ..Data are the first to show that surfactant may regulate lung homeostasis in part by inhibiting proinflammatory cytokine production through reduction of IKK and MAP kinase activity...
  20. ncbi request reprint Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis
    Daniel A Culver
    Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Respir Cell Mol Biol 30:1-5. 2004
    ....
  21. ncbi request reprint Elevated IL-10 inhibits GM-CSF synthesis in pulmonary alveolar proteinosis
    Mary Jane Thomassen
    Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195 5038, USA
    Autoimmunity 36:285-90. 2003
    ..Based on these observations, we hypothesize that IL-10 may be an indicator of PAP clinical response to GM-CSF therapy...
  22. ncbi request reprint Pulmonary alveolar proteinosis. Clinical manifestations and optimal treatment strategies
    Saiprakash B Venkateshiah
    Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Treat Respir Med 3:217-27. 2004
    ..Interventions directed at treating a relative GM-CSF deficiency by administration of GM-CSF or lowering the antibody level (i.e. by plasmapheresis or immunosuppression) may hold promise as future therapy for this rare disease...
  23. ncbi request reprint Serum cholestenoic acid as a potential marker of pulmonary cholesterol homeostasis: increased levels in patients with pulmonary alveolar proteinosis
    Steve Meaney
    Division of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    J Lipid Res 45:2354-60. 2004
    ....
  24. ncbi request reprint Elevated monocyte chemotactic proteins 1, 2, and 3 in pulmonary alveolar proteinosis are associated with chemokine receptor suppression
    Tracey L Bonfield
    Department of Pulmonary, Allergy and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Immunol 114:79-85. 2005
    ..Further, MCP-1 from PAP lung suppresses CCR2 expression in vitro, suggesting that in PAP, MCP-1 participates in an autocrine regulatory network in vivo...
  25. pmc Multiplexed particle-based anti-granulocyte macrophage colony stimulating factor assay used as pulmonary diagnostic test
    Tracey L Bonfield
    Department of Pulmonary, Allergy and Critical Care Medicine, 9500 Euclid Avenue, Cleveland Clinic Foundation, Desk A90, Cleveland, OH 44195 5038, USA
    Clin Diagn Lab Immunol 12:821-4. 2005
    ..In this report we present data to support anti-GM-CSF detection by a quantitative highly sensitive multiplexed particle-based assay which has the potential to be a clinical diagnostic test...
  26. ncbi request reprint An inverse relationship between peroxisome proliferator-activated receptor gamma and allergic airway inflammation in an allergen challenge model
    Michiko Kobayashi
    Respiratory Disease, Wyeth Research, Cambridge, Massachusetts, USA
    Ann Allergy Asthma Immunol 95:468-73. 2005
    ..Peroxisome proliferator-activated receptor gamma (PPAR-gamma) expression has not been evaluated in bronchoalveolar lavage (BAL) cells from allergic asthmatic patients...
  27. ncbi request reprint Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF
    Tracey L Bonfield
    Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland, OH, USA
    J Autoimmun 26:37-41. 2006
    ..These studies are the first to suggest that activin A may play a role in autoimmune disease...
  28. ncbi request reprint Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis
    Tracey L Bonfield
    Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Respir Cell Mol Biol 27:481-6. 2002
    ..Further, using anti-GM-CSF as an indicator of pulmonary alveolar proteinosis may avoid the use of more invasive means of evaluating patients with pulmonary disease characterized by alveolar infiltrates...

Research Grants2

  1. GM-CSF THERAPY FOR ALVEOLAR PROTEINOSIS
    Mary Jane Thomassen; Fiscal Year: 2003
    ..The applicants feel that these studies coupled with data from the GM-CSF clinical trial will provide novel insights into the basic mechanisms underlying human PAP. ..
  2. Cytokine Dysregulation in GM-CSF Autoimmunity
    Mary Jane Thomassen; Fiscal Year: 2007
    ..The rituximab trial offers a unique opportunity to explore effects of B cell depletion on PAP pulmonary AM function and at the same time investigate new therapy that may improve the lung disease in PAP. ..